INO-5150 enters initial clinical trials

Inovio Pharmaceuticals is initiating a Phase I trial of INO-5150 — a new type of immunotherapy for prostate cancer which targets both the prostate-specific antigen (PSA) and the and the prostate specific membrane antigen (PSMA). According to the media release from Inovio, this initial human trial will evaluate the effects of INO-5150 in men with biochemically recurrent prostate cancer when used alone and also when used in combination with another investigational drug known as INO-9012, which is a DNA-based IL-12 immune activator.

INO-5150 has previously demonstrated pre-clinical signals in a range of animal studies. In particular, INO-5150 was able to stimulate robust CD8+ T cell responses in these animal studies, and the T cells generated are fully functional — with a killing capacity that correlates with relevant clinical outcomes.

The immune responses generated by INO-5150 are apparently similar to the immune responses generated by VGX-3100, another investigational immunotherapeutic agent being studied by Inovio. VGX-3100 is active against human papilloma virus (HPV), has induced regression of pre-cancerous cervical lesions, and eliminated HPV in a randomized, placebo-controlled phase II trial.

As yet there is no information about this new trial on the web site, but we would expect such data to be available shortly. According to the company media release, the trial will be accessible through more than one clinical recruitment center, and you can contact the company directly by e-mail to seek more information.

In late 2013 Roche and Genentech did a deal with Inovio to move forward with the development of INO-5150. Apparently that deal either didn’t come to fruition or was terminated.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: